Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. - Wikidata - wikimedia - TriplyDB

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.

http://www.wikidata.org/entity/Q34608501

about

Light chain (AL) amyloidosis: update on diagnosis and management Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment Innovative agents in multiple myeloma Recurrent capillary leak syndrome following bortezomib therapy in a patient with relapsed myeloma.Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis.Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis.Amyloidosis and POEMS syndrome.Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.Complete atrioventricular block secondary to bortezomib use in multiple myeloma.Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation Kidney dysfunction during lenalidomide treatment for AL amyloidosis.Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial Amyloidosis: pathogenesis and new therapeutic options.Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.Current perspectives on cardiac amyloidosis.Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis The amyloidoses: clinical features, diagnosis and treatment.Al amyloidosis Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.Effectiveness of bortezomib in cardiac Al amyloidosis: a report of two cases.Long-term reversibility of renal dysfunction associated to light chain deposition disease with bortezomib and dexamethasone and high dose therapy and autologous stem cell transplantation.Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management.Cardiac amyloidosis: the heart of the matter.Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis.Dysregulation of miRNAs in AL amyloidosis.Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.Light-chain amyloidosis: SCT, novel agents and beyond.Immunoglobulin light chain amyloidosis.Future directions in the clinical management of amyloid light-chain amyloidosis.Novel strategies for the diagnosis and treatment of cardiac amyloidosis.Disease burden of systemic light-chain amyloidosis: a systematic literature review.Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity.Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib.Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement.Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.Decrease of B-type natriuretic peptide to less than 200 pg/mL predicts longer survival in cardiac immunoglobulin light chain amyloidosis.

P2860

Q21198863-4995F164-A279-4497-A0BE-EB9C5EB9AB83 Q26827340-397C48B0-BF74-4A79-BDAF-FC676718CEAE Q27022493-CA903DF3-51F7-4A4B-84B6-E6B2C741EB5C Q33388242-23D23694-ACAF-4E00-80DA-FAB300728374 Q33417805-976ADA7A-57EC-484E-8DA2-1D4E3306E7CD Q33427726-B1C72947-C556-42AE-8E71-6FB6B1E34692 Q33867198-887164DE-1ACA-4A74-8BA6-3066E2ED7195 Q34353682-5F178D65-6FB2-453D-BFBC-4FF75DE1573B Q34448455-E17FA12C-D7FD-4A50-9A82-A814B14AF814 Q34474586-3CDD707D-FB1A-4199-A526-B901A6BF742D Q34542087-10BF3188-6E45-42B7-8772-30D492C8D76D Q35025410-78A3783F-1AE0-4878-A3CC-C3C34B3E5EEA Q35081363-86A921CB-481C-4C93-8F47-D86E7C7130F6 Q35111771-9E23D319-235D-463F-851B-05CBF7A8FCF6 Q35895152-81610F04-C7F1-439F-BC06-AD819AEED582 Q35964900-63ADFF8C-92D7-4781-B2D7-7EFD0FF561DF Q36015183-A468AEB3-9DFB-4243-A5EB-F8B9880D8791 Q36036322-A1D76C8A-163A-4A9B-BAE2-35C4E34B488A Q36199790-966EE89E-C472-41D9-9D4C-9D2AD2FDAE6F Q36366997-795E6C28-9315-404B-B07E-7CCBD94749EE Q36392233-260D6FD5-CC2C-4B17-BBFA-31A37D7F5D41 Q37327280-0B5ABE63-DEE1-45F1-90EA-72A5DD4F51F1 Q37673360-3E8750D4-76DE-4B2B-AFD3-0DC2B98BD73F Q37694425-A43C12B7-1C2E-4A3F-86CF-9592FEF6FE39 Q37832199-7A263DBA-2490-4FBE-AD6C-4D0656518AB7 Q37899075-E02899DA-0F70-450F-BF04-79B2A7B4D6AB Q37904673-4DED8F78-61A2-43AF-BBDE-484BCA27C44B Q37915513-EADFE055-4B26-4BF3-8595-701ED7861B72 Q37999957-2DF4791A-546C-4D38-BCC1-7B74C026593C Q38056010-30574B87-B95D-4DB7-AE09-547DC67B6101 Q38172295-CE7DB2E3-1DFE-41F2-A461-9D18C9BED6EF Q38172998-0EC346B2-3961-42FE-8BE4-0D6F26F21CC9 Q38614967-0E837D13-DBE8-4303-B693-7F593300E41B Q38917828-DA2961C7-86E1-4E05-BB6B-F2FD2DEFFEE1 Q38928383-E3C09C88-CF32-41FB-87C9-A51CE3953112 Q38959241-642324D5-B2F7-4A31-B38B-0A68447BC28E Q39569161-797BADF7-015C-4319-870C-BA3175EFD964 Q40918755-FAA7C4B2-6938-48AB-9DDC-3A0B0572724F Q41593651-C2CDC8F9-B278-4F8B-A417-5DA4C7A566DB Q41714209-86E9A298-6E37-41A0-8C95-3DEF22A5D4D2

P2860

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.

http://www.wikidata.org/entity/Q34608501

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Weekly and twice-weekly bortez ...... phase 1 dose-escalation study.

@ast

Weekly and twice-weekly bortez ...... phase 1 dose-escalation study.

@en

Weekly and twice-weekly bortez ...... phase 1 dose-escalation study.

@nl

type

label

Weekly and twice-weekly bortez ...... phase 1 dose-escalation study.

@ast

Weekly and twice-weekly bortez ...... phase 1 dose-escalation study.

@en

Weekly and twice-weekly bortez ...... phase 1 dose-escalation study.

@nl

prefLabel

Weekly and twice-weekly bortez ...... phase 1 dose-escalation study.

@ast

Weekly and twice-weekly bortez ...... phase 1 dose-escalation study.

@en

Weekly and twice-weekly bortez ...... phase 1 dose-escalation study.

@nl

P1433

Q34608501-29BCE39F-5DE5-4B86-8830-E7B5953BC4A9

P1476

Q34608501-15B4A995-0B8B-4BA5-A7B1-9E5C5680049F

P2093

Q34608501-0161534B-678D-409C-868B-9ED591B133B8

Q34608501-07C204AB-0476-499F-88B3-7227EB8CF092

Q34608501-40C4EB25-734A-4030-92E2-79BB6FBF9A3E

Q34608501-508F6D46-E4AC-4138-B477-AA3AEE032745

Q34608501-681BAF64-398B-4677-B876-00256B293D58

Q34608501-89BD8C35-B3CC-4C22-93F7-E78E21C601D0

Q34608501-8AD0412C-80AC-40A7-B85B-8E4F237808E0

Q34608501-8C99CA3B-E66C-41B8-A101-D1DB4BF159DE

Q34608501-B065A2B1-8D0F-450D-B2F2-7A7E0DB946ED

Q34608501-B46DFF8D-6AA6-44E7-BA03-72CD5032FF1F

P304

Q34608501-0FC5D078-DF33-4311-AEEF-808EE37CFC11

P31

Q34608501-D0E90A65-A4BB-4A52-94B6-70FE0A101BF8

P356

Q34608501-EF1316DC-EB14-412D-9A1F-CFF6905766CF

P407

Q34608501-219E093F-2970-4AA4-9FD7-12EE3FDF708C

P433

Q34608501-F07BF1E0-9D8F-4626-B318-30E91D2EFBD3

P478

Q34608501-2F2E4586-99FB-4D67-BFB5-7D1B6EAC58EC

P577

Q34608501-C721A61D-FAA0-4E07-8BFE-FE3DD6530344

P5875

Q34608501-99A3DFCD-FDD3-4428-86C7-6F0F717BC4DF

P698

Q34608501-1E8E7425-BB99-41A0-A472-EBD49A60D656

P921

Q34608501-354373D3-F259-4D11-9975-DE0BD3E396FF

P356

BLOOD-2009-02-203398

P1433

P1476

Weekly and twice-weekly bortez ...... phase 1 dose-escalation study.

@en

P2093

Andrew Cakana

http://www.w3.org/2001/XMLSchema#string

Donna E Reece

http://www.w3.org/2001/XMLSchema#string

Giampaolo Merlini

http://www.w3.org/2001/XMLSchema#string

Giovanni Palladini

http://www.w3.org/2001/XMLSchema#string

Jean-Paul Fermand

http://www.w3.org/2001/XMLSchema#string

Raymond L Comenzo

http://www.w3.org/2001/XMLSchema#string

Robert A Vescio

http://www.w3.org/2001/XMLSchema#string

Ute Hegenbart

http://www.w3.org/2001/XMLSchema#string

VELCADE CAN2007 Study Group

http://www.w3.org/2001/XMLSchema#string

Vaishali Sanchorawala

http://www.w3.org/2001/XMLSchema#string

P304

1489-1497

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-02-203398

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26268240

http://www.w3.org/2001/XMLSchema#string

P698

19498019

http://www.w3.org/2001/XMLSchema#string

P921